Home Life Sciences Progestin effects in endometriosis treatment: new research on mechanisms
Article
Licensed
Unlicensed Requires Authentication

Progestin effects in endometriosis treatment: new research on mechanisms

  • Alfred O. Mueck EMAIL logo
Published/Copyright: December 1, 2010

Abstract

New research on mechanisms of progestin effects in endometriosis treatment has been performed with dienogest (DNG), which has recently been launched in this regard. It is effective in the same low dosage of 2 mg/day, similar to the use of contraception and hormone therapy, whereas other progestogens (with the exception of dydrogesterone) must be given in much higher dosages to treat typical symptoms of endometriosis. This short review summarizes experimental studies on DNG. They demonstrate strong antiproliferative effects in endometrial and endometriotic cells or experimental endometriosis, as well as anti-inflammatory and antiangiogenic actions. By direct action on the ovarian folliculogenesis DNG lead to only modest suppression of estradiol production in contrast to the high-dosed progestogens or to gonadotropin releasing hormone (GnRH) agonists. These effects add to the well-known tolerability because DNG is very neutral regarding cardiovascular, metabolic or central action which also makes it suitable for long-term therapy.


Corresponding author: Professor Alfred O. Mueck, MD, PharmD, PhD, University Women's Hospital, Department of Endocrinology and Menopause, Head, Center of Women's Health BW, Head, Calwer Strasse 7, D-72076 Tuebingen, Germany

Received: 2010-10-27
Accepted: 2010-11-3
Published Online: 2010-12-01
Published in Print: 2010-12-01

©2010 by Walter de Gruyter Berlin New York

Downloaded on 20.2.2026 from https://www.degruyterbrill.com/document/doi/10.1515/HMBCI.2010.061/html
Scroll to top button